Diminished clinical efficacy of imatinib therapy in c-KIT mutant melanoma may be a result of secondary acquired resistance caused by higher genetic mutation load, presence of activating or secondary c-KIT mutations, re-activation of redundant downstream survival signaling pathways, and/or tumor microenvironment cytokines [140,141,142,143,144]. This evidence concerns the gene KIT and melanoma.